Sanara MedTech (SMTI) Cash & Equivalents (2010 - 2026)

Sanara MedTech has reported Cash & Equivalents for 17 years, with the latest figure at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 34.29% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (down 34.29% YoY), and the FY2025 full-year result was $16.6 million, up 4.41% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $13.6 million, down from $16.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $20.7 million in Q1 2025, with the low at $2.8 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $11.6 million across 5 years, with a median of $12.7 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 61.18% — and 2025, when it soared 631.47%.
• Sanara MedTech's Cash & Equivalents stood at $9.0 million in 2022, then tumbled by 42.55% to $5.1 million in 2023, then surged by 208.48% to $15.9 million in 2024, then grew by 4.41% to $16.6 million in 2025, then dropped by 18.0% to $13.6 million in 2026.
• The last three Cash & Equivalents figures came in at $13.6 million (Q1 2026), $16.6 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.